IBMC
ibmc01 ibmc02 ibmc03 ibmc04 ibmc05 ibmc06 ibmc07 ibmc08 ibmc09 ibmc10 ibmc11 ibmc12
jQuery Image Slider by WOWSlider.com v2.0
web del Instituto de Biología Molecular y Celular
Dr. Miguel Saceda Sanchez

Unit: Molecular Diagnostic and Therapies
Subunit: Molecular and Cellular Oncology
Group: Chemoresistance and cancer
Category: Investigator
Phone: + 34 966 65 84 32
Email: msaceda@umh.es
Degree: Biology
Ph.D program: PhD degree, Universidad Complutense de Madrid (Director. Dra. Isabel Valverde Alonso), 1986.
Postdoctoral positions: 1. N I H, Bethesda, MD, U.S.A. Estrogen receptor and breast cancer. (1986-88).
2. Georgetown University, Washington DC, U.S.A. Estrogen receptor and breast cancer. (1988-1993).
3. Georgetown University, Washington D.C., U.S.A. Estrogen receptor and breast cancer. (1997-98).
4. Universidad Miguel Hernández. Biochemestry and Molecular Biology Deparment (Research contract Generalitat Valenciana). (1998-2000).
5. Hospital General Universitario de Elche (Research contract Spanish Healt Ministry). (2000-2006).
6. Fundación para la Investigación Biomédica del Hospital general Universitario de Elche. (2006-Actual).
Previous positions:
1. Fellowship from FIS (Ministerio de Sanidad). (1982-1985).
2. Fellowship from Spanish-USA joint Commite (1986-1988).
Current Position: Investigador de plantilla de la Fundación para la investigación Biomédica del Hospital general Universitario de Elche (Since 2006) and Associate professor of Biochemestry and Molecular Biology (since 2000).
Research Fields:
1. Molecular mechanisms of cancer cells chimiorresistance.
2. Development of new cancer treatment for chemoresistance tumours.
3. Histone deacetylase inhibitors as new therapeutics drugs in cancer.
4. Molecular mechanisms of apoptosis as potential new targets in cancer.
Representative Publications:

  • Castro-Galache M.D., Ferragut, J.A., Barberá V.M., García-Morales, P., González-Ros, J.M., Saceda, M. Apoptosis induction and down-regulation of P-glycoprotein by Trichostatin A in a Daunorubicin-Resistant murine leukemia cell line. 2003. Int. J. Cancer 104, 579-586.
  • García-Morales, P., Gomez-Martinez, A., Carrato, A., Martinez-Lacaci, M.I., Barbera, V.M., Soto, J.L., Carrasco-García, E., Menéndez-Gutierrez, M.P., Castro-Galache, M.D., Ferragut, J.A., Saceda, M. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther. 2005. 4(8), 1222-1230
  • García-Morales, P., Hernando, E., Carrasco-Garcia, E., Menéndez-Gutierrez, M.P., Saceda, M., Martinez-Lacaci, I. Cyclin D3 is down regulated by rapamycin in HER2-overexpresing breast cancer cells. Mol. Cancer Therap. 2006. 5(9), 2172-2181.
  • García-Morales P., Carrasco-García E., Ruiz-Rico P., Martínez-Mira R., Menéndez-Gutiérrez MP., Ferragut JA., Saceda M., Martínez-Lacaci I. Inhibition of Hsp90 function by ansamycin causes downregualtion of cdc2 and cdc25c and G(2)M arrest in glioblastoma cell lines. 2007. Oncogene 26(51), 7185-93.
  • Gomez-Martinez, A., García-Morales, P., García-Poveda, E., Carrato, A., Castro-Galache, M.D., Soto, J.L., Ferragut, J.A., Saceda, M. Post-transcriptional regulation of P-glycoprotein expresión in colon carcinoma cell lines. 2007. Mol. Cancer Res. 5(6), 641-653.